MX2017013206A - Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada. - Google Patents

Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada.

Info

Publication number
MX2017013206A
MX2017013206A MX2017013206A MX2017013206A MX2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A MX 2017013206 A MX2017013206 A MX 2017013206A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
nucleotide sequence
composition based
transgene expression
optimized nucleotide
Prior art date
Application number
MX2017013206A
Other languages
English (en)
Inventor
Lvovich Kiselev Sergey
Original Assignee
Company Ltd Nextgen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Company Ltd Nextgen filed Critical Company Ltd Nextgen
Publication of MX2017013206A publication Critical patent/MX2017013206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Abstract

Se han identificado cambios puntuales a la secuencia de nucleótidos 3´UTR del gen VEGF que incrementan significativamente el lapso de vida del producto de transcripción de mRNA del gen en las células de mamífero. Un constructo de gen con una lista óptima de las mutaciones identificadas, que se caracteriza por un lapso de vida de mRNA máximo, se ha seleccionado por experimentación. El efecto biológico del constructo de gen desarrollado y de una composición farmacéutica en base al mismo se ha confirmado in vitro e in vivo.
MX2017013206A 2015-05-26 2015-12-07 Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada. MX2017013206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015119768A RU2612497C2 (ru) 2015-05-26 2015-05-26 Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
PCT/RU2015/000852 WO2016190774A1 (ru) 2015-05-26 2015-12-07 Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf

Publications (1)

Publication Number Publication Date
MX2017013206A true MX2017013206A (es) 2018-02-15

Family

ID=57392933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013206A MX2017013206A (es) 2015-05-26 2015-12-07 Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada.

Country Status (10)

Country Link
US (2) US9896493B2 (es)
EP (1) EP3305901B1 (es)
CN (1) CN107614687B (es)
AU (1) AU2015396177B2 (es)
BR (1) BR112017023058B1 (es)
CA (1) CA2985608C (es)
EA (1) EA039395B1 (es)
MX (1) MX2017013206A (es)
RU (1) RU2612497C2 (es)
WO (1) WO2016190774A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114908089B (zh) * 2021-02-08 2024-03-15 上海细胞治疗集团有限公司 3’utr的构建方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
EP0973926A1 (en) 1997-03-14 2000-01-26 Selective Genetics, Inc. Adenoviral vectors with modified tropism
US6627436B2 (en) 1997-10-31 2003-09-30 Stratagene Vector for gene expression in prokaryotic and eukaryotic systems
BR9908754A (pt) 1998-03-13 2000-11-28 American Home Prod Composições liofilizada e lìquida de polinucleotìdeo e farmacêutica, processos para tratar um paciente mamìfero e para preparar uma composição liofilizada de polinucleotìdeo, produto liofilizado de polinucleotìdeo, e, processo para liofilizar uma composição de polinucleotìdeo
US7598079B2 (en) * 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
WO2000047235A2 (en) 1999-02-10 2000-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of stimulating angiogenesis
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7288521B2 (en) 2000-04-06 2007-10-30 Franco Wayne P Growth factor therapy mobilization of stem cells into the peripheral blood
CN1351055A (zh) 2000-10-26 2002-05-29 上海博德基因开发有限公司 一种新的多肽——人的血管内皮生长因子165受体(vegf－165r)10.67和编码这种多肽的多核苷酸
CA2451311A1 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
CN100431611C (zh) 2002-07-04 2008-11-12 朱静亚 多肽－脂质体与人血管内皮生长因子基因重组质粒复合物及用途
CA2507534A1 (en) 2002-12-02 2004-06-17 Anges Mg, Inc. Methods for treating or preventing angiogenesis-dependent symptoms
EP1791945A1 (en) 2004-09-17 2007-06-06 Centelion Stable liquid formulations of plasmid dna
RU2297848C2 (ru) 2005-05-11 2007-04-27 Александр Веньяминович Иткес Генно-инженерная конструкция vegf-ибмед (vegf-ibmed)
ES2338400B1 (es) 2008-05-06 2011-09-14 David Benet Ferrus Conjunto de moleculas antiangiogenicas y su uso.
WO2010098861A1 (en) 2009-02-24 2010-09-02 The Scripps Research Institute Reengineering mrna primary structure for enhanced protein production
US8367350B2 (en) 2009-04-29 2013-02-05 Morehouse School Of Medicine Compositions and methods for diagnosis, prognosis and management of malaria
RU2431669C2 (ru) * 2009-06-23 2011-10-20 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный университет им. В.И. Ульянова-Ленина" Способ получения лекарственного препарата генетически модифицированных клеток
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека

Also Published As

Publication number Publication date
RU2015119768A (ru) 2016-12-20
EP3305901A1 (en) 2018-04-11
BR112017023058A2 (pt) 2018-10-16
US10040837B2 (en) 2018-08-07
CN107614687A (zh) 2018-01-19
US20160347803A1 (en) 2016-12-01
AU2015396177B2 (en) 2019-02-28
US20180086800A1 (en) 2018-03-29
BR112017023058B1 (pt) 2024-03-05
RU2612497C2 (ru) 2017-03-09
CN107614687B (zh) 2021-05-28
EP3305901B1 (en) 2020-09-30
EA201700456A1 (ru) 2018-06-29
US9896493B2 (en) 2018-02-20
EA039395B1 (ru) 2022-01-21
EP3305901A4 (en) 2018-10-24
WO2016190774A1 (ru) 2016-12-01
CA2985608A1 (en) 2016-12-01
CA2985608C (en) 2021-06-15
AU2015396177A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
EP3728596A4 (en) CONSTRUCTION OF NUCLEIC ACID ALLOWING THE EXPRESSION OF A GENE IN VITRO AND IN VIVO
ECSP19017082A (es) Regulación de la expresión génica usando nucleasas modificadas
PH12019501262A1 (en) Modified guide rnas
MX2021005226A (es) Regulacion de expresion genica mediada por nucleasa.
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
AR092317A1 (es) Vectores virales para el tratamiento de distrofia retiniana
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
MX2016017296A (es) Sintasa del acido cannabicromenico proveniente de cannabis sativa.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
PH12015500213A1 (en) Production of fmdv-resistant livestock by allele substitution
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
MX2021009554A (es) Produccion de virus en cultivos celulares.
WO2013060819A3 (en) Transient expression vectors, preparation and uses thereof
WO2014118817A3 (en) Platelets transfected by exogenous genetic material and platelet microparticles obtained by said transfected platelets, method for the preparation and uses thereof
IN2014DN10111A (es)
IL276424A (en) A special promoter for oligodendrocytes, a special mirna for the plp1 gene, a vector including the above-mentioned promoter and/or mirna, and a pharmaceutical composition including the above-mentioned vector
MX2017013206A (es) Secuencia de nucleotidos optimizada y composicion farmaceutica basada en la misma con expresion de transgen vegf prolongada.
MX2016013363A (es) Metodo para aumentar la capacidad de sintesis de biomasa de microorganismos y microorganismos modificados a partir de ellos.
AR110625A1 (es) Regulación de la expresión de genes utilizando nucleasas modificadas por ingeniería genética
Skrotska et al. THE CYTOTOXIC EFFECT OF THE DRUG IZATIZON ON THE CULTURE OF НЕК-293
WO2013083329A3 (en) Transient lentiviral expression vectors, preparation and uses thereof